Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Conditions:   Leiomyosarcoma;   Myxofibrosarcoma;   Resectable Dedifferentiated Liposarcoma;   Resectable Soft Tissue Sarcoma;   Resectable Undifferentiated Pleomorphic Sarcoma;   Soft Tissue Fibrosarcoma;   Spindle Cell Sarcoma;   Stage I Retroperitoneal Sarcoma American Joint Committee on Cancer (AJCC) v8;   Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage IA Retroperitoneal Sarcoma AJCC v8;   Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage IB Retroperitoneal Sarcoma AJCC v8;   Stage IB Soft Tissue Sarcoma of the Tru nk and Extremities AJCC v8;   Stage II Retroperitoneal Sarcoma AJCC v8;   Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Storiform-Pleomorphic Malignant Fibrous Histiocytoma;   Synovial Sarcoma;   Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells;   Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant Interventions:   Procedure: Definitive Surgical Resection;   Drug: Immunotherapeutic Agent;   Biological: Nivolumab;   Radiation: Radiation Therapy Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials